Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1446902

Bial Group - Product Pipeline Review - Q1 2011

Description:
Bial Group – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Bial Group - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bial Group - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bial Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bial Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bial Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bial Group’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bial Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bial Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bial Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bial Group and identify potential opportunities in those areas.
 
Contents:


List of Tables
List of Figures
Bial Group Snapshot
Bial Group Overview
Key Information
Key Facts
Bial Group – Research and Development Overview
Key Therapeutic Areas
Bial Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Bial Group – Pipeline Products Glance
Bial Group – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Bial Group Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Bial Group–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Bial Group – Drug Profiles
BIA 2-093
Product Description
Mechanism of Action
R&D Progress
BIA 9-1067
Product Description
Mechanism of Action
R&D Progress
Stedesa
Product Description
Mechanism of Action
R&D Progress
BIA 5-1058
Product Description
Mechanism of Action
R&D Progress
BIA 10
Product Description
R&D Progress
BIA 12
Product Description
R&D Progress
BIA 13
Product Description
R&D Progress
BIA-10-2474
Product Description
Mechanism of Action
R&D Progress
Bial Group – Pipeline Analysis
Bial Group – Pipeline Products by Therapeutic Class
Bial Group - Pipeline Products By Target
Bial Group – Pipeline Products by Route of Administration
Bial Group – Pipeline Products by Molecule Type
Bial Group – Recent Pipeline Updates
Bial Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Bial Group Detailed Deal Summary
Acquisition
Fornix BioSciences Terminates The Acqusition Of Bial-Aristegui
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Bial Group – Pipeline by Therapy Area and Indication, 2011
Bial Group – Pipeline by Stage of Development, 2011
Bial Group – Monotherapy Products in Pipeline, 2011
Bial Group – Phase III, 2011
Bial Group - Phase I, 2011
Bial Group - Pipeline By Therapeutic Class, 2011
Bial Group - Pipeline By Target, 2011
Bial Group – Pipeline By Route of Administration, 2011
Bial Group – Pipeline By Molecule Type, 2011
Bial Group – Recent Pipeline Updates, 2011
Bial Group, Other Locations

List of Figures
Bial Group – Pipeline by Therapy Area and Indication, 2011
Bial Group – Pipeline by Stage of Development, 2011
Bial Group – Monotherapy Products in Pipeline, 2011
Bial Group – Pipeline By Therapeutic Class, 2011
Bial Group - Pipeline By Target, 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1446902

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Oct 25th 2014
7:01:35 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Bial Group - Product Pipeline Review - Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1446902

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Oct 25th 2014
7:01:35 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)